Evaluation of the GeneTex U‐OK SARS‐CoV‐2 Neutralizing Antibody Detection Assay: Comparison With GenScript cPass and Viral Neutralization Assays
Journal of Medical Virology · 2026
DOI: 10.1002/jmv.70771 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Journal of Medical Virology, 2026. Verfasst von Hui-Ju Lin und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Laboratory Medicine, China Medical University Hospital, China Medical University, Taichung, Taiwan. Hauptthemen laut MEDLINE: Antibodies, Neutralizing, Antibodies, Viral, Neutralization Tests, SARS-CoV-2. Die Arbeit nennt 25 Literaturangaben. Gefördert von: China Medical University, Taichung, Taiwan.
Abstract (Originalsprache)
The detection of neutralizing antibodies (NAbs) is crucial for evaluating immune protection against viral infections. This study assessed two ELISA‐based surrogate virus neutralization tests (sVNTs): the novel GeneTex U‐OK SARS‐CoV‐2 Neutralizing Antibody Detection ELISA kit and the FDA‐authorized GenScript cPass SARS‐CoV‐2 Neutralization Antibody Detection kit. The GeneTex U‐OK kit contains recombinant spike proteins from the wild‐type strain and Omicron subvariants BA.1, BA.2, and BA.4/BA.5. A total of 115 serum samples were analyzed, including 75 from SARS‐CoV‐2 unvaccinated individuals and 40 from vaccinated individuals. No participant had evidence of prior SARS‐CoV‐2 infection, as confirmed by negative anti‐nucleocapsid antibody tests. Compared with the GenScript cPass kit, the GeneTex U‐OK kit demonstrated 100% positive agreement (95% CI: 90.4–100.0%) and 100% negative agreement (95% CI: 95.4–100.0%) in detecting NAbs against the wild‐type strain, corresponding to 100% sensitivity and 100% specificity. When compared with viral neutralization assays, it achieved 100% concordance for Omicron BA.1, BA.2, and BA.4/BA.5 subvariants, with correlation coefficients (R) of 0.85, 0.98, and 0.46, respectively. These findings highlight the accuracy and reliability of the GeneTex U‐OK kit, indicating its potential as a valuable tool for monitoring vaccine effectiveness and identifying individuals with protective NAbs against vaccinated individuals, including Omicron variants.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Laboratory Medicine, China Medical University Hospital, China Medical University, Taichung, Taiwan.
- International Master's Program of Biomedical Sciences, China Medical University, Taichung, Taiwan.
- Department of Medical Research, China Medical University Hospital, Taichung, Taiwan.
- Drug Development Center, China Medical University, Taichung, Taiwan.
- Department of Clinical Laboratory Sciences and Medical Biotechnology, College of Medicine, National Taiwan University, Taipei, Taiwan.
- Department of Laboratory Medicine, College of Medicine, National Taiwan University Hospital, National Taiwan University, Taipei, Taiwan.
ORCID-Profile: Po-Ren Hsueh
Förderung
- China Medical University, Taichung, Taiwan
Zitieren
APA
Lin, H. J., Su, W. C., Wen, H. Y., Hung, C. H., Chang, S. Y., & Hsueh, P. R. (2026). Evaluation of the GeneTex U‐OK SARS‐CoV‐2 Neutralizing Antibody Detection Assay: Comparison With GenScript cPass and Viral Neutralization Assays. Journal of Medical Virology. https://doi.org/10.1002/jmv.70771
Vancouver
Lin HJ, Su WC, Wen HY, Hung CH, Chang SY, Hsueh PR. Evaluation of the GeneTex U‐OK SARS‐CoV‐2 Neutralizing Antibody Detection Assay: Comparison With GenScript cPass and Viral Neutralization Assays. Journal of Medical Virology. 2026. doi:10.1002/jmv.70771
BibTeX
@article{Lin2026,
author = {Lin, Hui-Ju and Su, Wen-Chi and Wen, Hsu-Yu and Hung, Cheng-Hao and Chang, Sui-Yuan and Hsueh, Po-Ren},
title = {Evaluation of the GeneTex U‐OK SARS‐CoV‐2 Neutralizing Antibody Detection Assay: Comparison With GenScript cPass and Viral Neutralization Assays},
journal = {Journal of Medical Virology},
year = {2026},
doi = {10.1002/jmv.70771}
}
EUVIMED